Identification and validation of H. pylori-associated gastric cancer biomarkers in Chinese and German populations

中国和德国人群中幽门螺杆菌相关胃癌生物标志物的鉴定和验证

• 批准号: 410192478
• 负责人: Professor Dr. Markus Gerhard
• 金额: --
• 依托单位: Beijing Cancer Hospital
• 依托单位国家: 德国
• 项目类别: Research Grants
• 财政年份: 2019
• 资助国家: 德国
• 起止时间: 2018-12-31 至 2022-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/410192478?language=en
• 关键词: Identification; validation; H.; pylori; associated

Gastric cancer (GC) is the third leading cause of cancer-related deaths worldwide, with incidence being especially high in Asia. The development of gastric tumors is a multifactorial process in which infection with Helicobacter pylori is the main risk factor, while the individual risk is modulated by genetic and epigenetic factors. The chronic infection activates a number of inflammatory signaling pathways and induces DNA damage, contributing to the development and progression of precursor gastric lesions to GC. Late detection due to the lack of efficient biomarkers for early diagnosis as well as limited therapeutic strategies are the major reasons for the low prognosis observed in GC patients. Different studies have aimed at identifying novel biomarkers to improve early detection by non-invasive means, however, no single marker with sufficient predictive power to identify early stages has been demonstrated so far. Thus, the identification of biomarkers is an important aspect to address this high medical need. Importantly, the detection of biomarkers by non-invasive methods is of major significance for general clinical practice, especially in countries where prevalence is high and gastroscopic screening is not readily available for the broad population. This situation is found in many Asian countries. Therefore, we aim at establishing a screening algorithm for GC associated with H. pylori infection based on a combination of biomarkers detectable in peripheral blood which can be utilized to screen populations at high risk. This predictive model might eventually represent a powerful tool with a major impact on GC morbidity and mortality.

胃癌（GC）是全球癌症相关死亡的第三大原因，亚洲的发病率尤其高。胃肿瘤的发生是一个多因素的过程，其中幽门螺杆菌感染是主要的危险因素，而个体风险受到遗传和表观遗传因素的调节。慢性感染激活了许多炎症信号通路并诱导DNA损伤，有助于胃癌前体病变的发展和进展。由于缺乏早期诊断的有效生物标志物以及有限的治疗策略而导致的晚期检测是GC患者中观察到的低预后的主要原因。不同的研究旨在鉴定新的生物标志物，以通过非侵入性手段改善早期检测，然而，迄今为止还没有证明具有足够预测能力的单一标志物来鉴定早期阶段。因此，生物标志物的鉴定是解决这种高医疗需求的重要方面。重要的是，通过非侵入性方法检测生物标志物对于一般临床实践具有重要意义，特别是在患病率高且胃镜筛查不容易用于广泛人群的国家。这种情况在许多亚洲国家都存在。因此，我们的目标是建立一个筛选算法，GC与H。幽门螺杆菌感染的检测基于外周血中可检测的生物标志物的组合，其可用于筛选高危人群。这种预测模型可能最终代表一个强大的工具，对GC的发病率和死亡率产生重大影响。